J Korean Ophthalmol Soc > Volume 59(7); 2018 > Article
Journal of the Korean Ophthalmological Society 2018;59(7):650-656.
DOI: https://doi.org/10.3341/jkos.2018.59.7.650    Published online July 15, 2018.
Combined Low Dose Bevacizumab-triamcinolone versus Bevacizumab Single Intravitreal Injection for Branch Retinal Vein Occlusion.
Min Ho Shin, Hyun Ji Kang, Jin Seok Seo, In Young Chung
1Department of Ophthalmology, Gyeongsang National University College of Medicine, Jinju, Korea. in0chung@hanmail.net
2Gyeongsang Institute of Health Sciences, Gyeongsang National University, Jinju, Korea.
분지망막정맥폐쇄에서 베바시주맙군과 저용량 베사시주맙-트리암시놀론 혼합군의 단기 효과 비교
신민호1⋅강현지1⋅서진석1⋅정인영1,2
경상대학교 의과대학 안과학교실1, 경상대학교 건강과학연구원2
Correspondence:  In Young Chung,
Email: in0chung@hanmail.net
Received: 12 April 2018   • Revised: 25 April 2018   • Accepted: 22 June 2018
Abstract
PURPOSE
To report the effects of combined low dose bevacizumab and low dose triamcinolone intravitreal injection compared with single bevacizumab intravitreal injection in patients with macular edema secondary to branch retinal vein occlusion. METHODS: Thirty eyes of 30 patients diagnosed with branch retinal vein occlusion were evaluated. The combined injection group (15 eyes of 15 patients) was treated with intravitreal injection of combined low dose bevacizumab (0.625 mg/0.025 mL) and low dose triamcinolone (1 mg/0.025 mL). The single injection group (15 eyes of 15 patients) was treated with intravitreal injection of bevacizumab (1.25 mg/0.05 mL). The best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP) of treated eyes were measured before injection and at 1 month, 2 months, and 3 months after injection. RESULTS: In the combined injection group, the BCVA increased significantly at 1 month, 2 months, and 3 months after injection (p < 0.05). However, in the single injection group, the BCVA increased significantly only at 3 months after injection (p < 0.05). In both groups, the CMT decreased significantly at 1 month, 2 months, and 3 months after injection (p < 0.05). The IOP showed no significant change at 3 months after injection (p > 0.05) in both groups. The BCVA, CMT, and IOP after injection showed no significant differences between the combined injection group and the single injection group (p > 0.05). CONCLUSIONS: The combined intravitreal injection of low dose bevacizumab and low dose triamcinolone may be useful and safe for the treatment of macular edema secondary to branch retinal vein occlusion.
Key Words: Bevacizumab;Combined;Intravitreal injection;Low dose;Triamcinolone


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2021 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next